Lefuheal
✅ Manages rheumatoid arthritis
✅ Vermindert gewrichtsontsteking
✅ Vertraagt de ziekteprogressie
✅ Verbetert de gewrichtsfunctie
✅ Contains Leflunomide
Lefuheal contains Leflunomide.
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
⚡ Quick Answer — What is Lefuheal?
Lefuheal is an oral tablet from Healing Pharma containing leflunomide 10 mg and 20 mg — an oral conventional synthetic DMARD (disease-modifying antirheumatic drug) that inhibits dihydroorotate dehydrogenase, blocking de-novo pyrimidine synthesis in activated lymphocytes. Used primarily for moderate-to-severe rheumatoid arthritis en active psoriatic arthritis, usually after methotrexate has failed or as a methotrexate alternative. Standard adult dose: 20 mg eenmaal daags (10 mg once daily if intolerance); some prescribers use a 100 mg/day × 3-day loading dose, but this raises early hepatotoxicity and diarrhoea rates and is increasingly skipped in routine practice. Onset is slow — 4–6 weeks for early benefit, 12–24 weeks for full effect. The drug's active metabolite (teriflunomide) has an exceptionally long half-life (~14 days from a single dose, much longer with steady-state enterohepatic recirculation) — a feature that makes it convenient (once-daily dosing, missed dose forgiveness) but also means cholestyramine washout is mandatory for pregnancy planning, severe adverse reaction, or rapid switch to another therapy. Pregnancy Category X — both female AND male patients on leflunomide must use effective contraception. Hepatotoxicity is the major safety concern; monthly LFT/CBC/BP for 6 months then quarterly.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.
What Is Lefuheal?
Lefuheal is an oral tablet manufactured by Healing Pharma containing leflunomide — a conventional synthetic disease-modifying antirheumatic drug (DMARD). Leflunomide itself is a pro-drug that is rapidly converted in the gut and liver to its active metabolite teriflunomide (also marketed as a separate drug for multiple sclerosis under the brand name Aubagio).
Lefuheal is Healing Pharma's branded generic leflunomide — available at both 10 mg and 20 mg strengths to support flexible dose titration. The 20 mg tablet is the standard maintenance dose; the 10 mg tablet is used for dose reduction in patients with intolerance (particularly diarrhoea, hair thinning, or mild ALT rise) and for elderly or low-body-weight patients. Leflunomide has been in routine rheumatology practice since the late 1990s; it is one of the few oral DMARDs with proven equivalent efficacy to methotrexate in rheumatoid arthritis. It is used either alongside methotrexate in resistant disease, or as the principal DMARD when methotrexate is not tolerated.
How Does Lefuheal Work?
The active metabolite teriflunomide selectively inhibits dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme central to de-novo pyrimidine synthesis. Activated, rapidly-dividing lymphocytes depend almost entirely on this de-novo pathway for the nucleotides they need to proliferate; resting and slowly-dividing cells can bypass DHODH using the salvage pathway.
The result is a selective brake on activated T-cell and B-cell proliferation:
- Reduced T-cell expansion in inflamed joints and synovium
- Reduced B-cell proliferation and autoantibody production
- Reduced cytokine production (IL-2, IFN-γ, TNF-α) by activated lymphocytes
- Some additional anti-inflammatory and matrix-protective effects in joint synovium independent of pyrimidine synthesis
Pharmacokinetic features that matter clinically:
- Active metabolite teriflunomide has a half-life of ~14 days from a single dose. With steady-state dosing and enterohepatic recirculation, effective half-life can be much longer — meaning the drug stays measurable in plasma for months after stopping.
- This is why cholestyramine washout (8 g three times daily for 11 days) is needed if rapid drug elimination is required — for pregnancy planning, severe adverse reaction, or rapid switch to a different therapy.
- Onset of clinical benefit is slow: 4–6 weeks for first signs of improvement, 12–24 weeks for full effect. Patients often want to give up early; the slow time-course must be set as expectation from the start.
Toepassingen en Indicaties
- Moderate-to-severe rheumatoid arthritis — the principal indication. Used as monotherapy when methotrexate is not tolerated, or in combination with methotrexate for resistant disease.
- Active psoriatic arthritis — particularly with peripheral joint involvement; less effective for axial disease.
- Off-label: severe inflammatory and autoimmune conditions — lupus arthritis, Felty's syndrome, sarcoidosis, severe pyoderma gangrenosum, ANCA-associated vasculitis maintenance, juvenile idiopathic arthritis.
- Off-label: BK virus nephropathy in renal transplant — uses the antiviral side-effect of pyrimidine inhibition.
Lefuheal is niet appropriate for: ankylosing spondylitis (no axial benefit), mild rheumatoid arthritis (sulfasalazine or hydroxychloroquine first), short-term symptom relief (the drug takes weeks to work), or patients who cannot commit to monthly blood tests for at least 6 months.
Lefuheal Dosage and How to Take
Lefuheal is supplied at 10 mg and 20 mg. Standard adult dosing is straightforward but requires careful upfront planning around contraception and baseline monitoring.
Dosing options
| Approach | Regime | Trade-off |
|---|---|---|
| Loading dose (traditional) | 100 mg once daily for 3 days, then 20 mg once daily | Faster steady-state by ~2 weeks but higher rates of early diarrhoea, hepatotoxicity, and discontinuation |
| No-loading (preferred in modern practice) | 10–20 mg once daily from day one | Slower to steady-state; better tolerated; lower discontinuation. Steady-state reached at 8–12 weeks. |
| Reduced dose for tolerability | 10 mg once daily ongoing | Useful when 20 mg/day causes intolerable diarrhoea; some loss of efficacy |
| Combination with methotrexate | 10–20 mg leflunomide + standard methotrexate | Higher efficacy but additive hepatotoxicity and infection risk; closer monitoring required |
How to Take Lefuheal Properly
- Take the same dose at the same time once daily, with or without food — food has minimal effect on absorption.
- Swallow the tablet whole with water. Do not crush or split.
- Do not start without a baseline plan — baseline LFTs, CBC, BP, pregnancy test (women of childbearing age), confirmation of effective contraception in BOTH partners, screening for latent TB and chronic viral hepatitis where indicated.
- Get monthly LFT, CBC and BP for the first 6 months, then quarterly long-term. This is non-negotiable. Any rise in ALT or AST above 2–3× the upper limit of normal must trigger a prescriber review and usually a dose reduction or interruption.
- Effective contraception is mandatory for women of childbearing age throughout treatment AND for at least 2 years after stopping (or until cholestyramine washout has confirmed plasma teriflunomide level < 0.02 mg/L on two separate samples 14 days apart). Male partners on leflunomide whose female partner could become pregnant should also use barrier contraception — teriflunomide is detectable in semen.
- Avoid live vaccines during therapy. Inactivated vaccines (annual flu, pneumococcal, COVID-19, recombinant Shingrix) are fine and recommended; ideally given before starting.
- Tell every healthcare provider you take Lefuheal — especially before any new prescription, surgery, or pregnancy planning.
- Avoid hepatotoxic drugs and limit alcohol — combined with methotrexate or alcohol, leflunomide hepatotoxicity rises sharply. Most rheumatologists advise no more than 1–2 alcoholic units per week.
- Be patient — first signs of benefit at 4–6 weeks; full effect at 12–24 weeks. Do not stop the drug at week 4 because “it isn't working”.
Cholestyramine Washout — Why and When
The active metabolite teriflunomide undergoes enterohepatic recirculation: it is excreted in bile, reabsorbed in the gut, and returned to the bloodstream. This is why teriflunomide stays measurable in plasma for many months after stopping leflunomide, and why a special washout is needed when rapid elimination is required.
Cholestyramine (an oral bile-acid sequestrant) binds teriflunomide in the gut, breaking the enterohepatic loop and dramatically accelerating elimination.
Standard washout protocol:
- Cholestyramine 8 g three times daily for 11 days (alternative: activated charcoal 50 g four times daily for 11 days)
- Then check plasma teriflunomide level — should be < 0.02 mg/L
- Re-check on a second separate sample taken at least 14 days later to confirm sustained washout
- Only after both samples are below the threshold can pregnancy be safely planned
When to use the washout protocol:
- Planned pregnancy in a female patient (regardless of how recently leflunomide was stopped)
- Unplanned pregnancy on leflunomide — immediate cholestyramine + obstetric input
- Severe adverse reaction (severe hepatotoxicity, severe rash, severe cytopenia, severe interstitial lung disease)
- Rapid switch to a biologic or other DMARD where teriflunomide co-presence would compound risk
- Acute overdose
Without the washout, teriflunomide can persist in plasma for up to 2 years.
Side Effects of Lefuheal
Leflunomide is generally tolerated similarly to methotrexate — about 1 in 5 patients stop the drug within the first year because of side effects.
Common (> 10%):
- Diarree — 17–25% of patients; usually starts in first 2–3 months; often improves with dose reduction to 10 mg/day or temporary cholestyramine
- Hair thinning, alopecia — 10–20%; usually mild; reversible after stopping
- Nausea, abdominal pain
- Hypertensie — 10%; manage as standard
- Mild ALT/AST rise — common; usually settles or responds to dose reduction
- Hoofdpijn
- Skin rash — mild; rarely severe
Uncommon to rare but serious:
- Severe hepatotoxicity — rare but with reported deaths; risk highest in first 6 months. Higher with combination methotrexate or alcohol use.
- Pancytopenia, agranulocytosis, severe thrombocytopenia
- Interstitial lung disease — new dyspnoea or non-productive cough during treatment must be investigated; risk highest in patients with pre-existing ILD or pulmonary disease.
- Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS)
- Ernstige infectie (TB reactivation, opportunistic fungal, severe varicella, Pneumocystis)
- Perifere neuropathie — usually reversible after stopping (with cholestyramine washout)
- Hypertensive emergency — rare; manage as standard
- Lymphoma — small absolute increase, parallel to other immunosuppressants
Pregnancy and fertility:
- Strongly teratogenic in animal models — embryolethal and teratogenic in rats and rabbits at human-equivalent doses
- Human teratogenicity is less clearly established but the precautionary principle applies — rated Pregnancy Category X
- Both female AND male partners must use effective contraception during therapy
Waarschuwingen en voorzorgsmaatregelen
- Pre-existing hepatic impairment — absolute contraindication for moderate-to-severe disease; relative for mild disease.
- Active or untreated infection — defer until cleared.
- Latent TB, hepatitis B/C — screen before starting; treat as appropriate.
- Hypertensie — control before starting; monitor BP monthly during first 6 months.
- Severe immunodeficiency — absolute contraindication.
- Marked hypoproteinaemia (e.g. severe nephrotic syndrome) — teriflunomide is highly protein-bound; low albumin gives unpredictable free-drug levels. Use with caution.
- Zwangerschap — contraindicated. Effective contraception throughout therapy and at least 2 years after stopping (or until washout-confirmed below threshold). Discuss family planning at every review.
- Borstvoeding — contraindicated; teriflunomide passes into milk.
- Kinderen — not licensed for general paediatric use, though sometimes used for juvenile idiopathic arthritis under specialist supervision.
- Ouderen — no specific dose adjustment needed but more vulnerable to GI side effects, infection and hepatotoxicity.
- Live vaccines — contraindicated during therapy and for 2 years after stopping (or until washout confirmed). Plan all live vaccines BEFORE starting.
- Operatie — no need to stop leflunomide for elective surgery in most patients; the long half-life makes brief peri-operative withholding ineffective. Discuss with the rheumatologist.
Contraindications — Who Should NOT Take Lefuheal
- Known hypersensitivity to leflunomide or teriflunomide
- Moderate or severe hepatic impairment (Child-Pugh B or C)
- Severe immunodeficiency (HIV/AIDS, congenital immunodeficiency, severe combined immunodeficiency)
- Severe untreated infection
- Significant pre-existing bone-marrow suppression
- Severe hypoproteinaemia (severe nephrotic syndrome)
- Pregnancy or breastfeeding
- Childbearing potential without effective contraception
- Recent live vaccine or planned live vaccine in the next 3 months
Geneesmiddelinteracties
| Combineren met | Effect | Wat te doen |
|---|---|---|
| Methotrexaat | Synergy in disease control AND additive hepatotoxicity / cytopenia | Common combination; intensify monitoring (LFT/CBC every 2 weeks × 8, then monthly). |
| Other hepatotoxic drugs (paracetamol high-dose, alcohol, isoniazid, ketoconazole, anti-epileptics) | Compound hepatotoxicity | Use the lowest effective doses, monitor LFTs more frequently, limit alcohol to ≤ 1–2 units/week. |
| Warfarine | Variable INR rise (mechanism unclear) | Check INR within 1–2 weeks of starting or stopping leflunomide; adjust warfarin as needed. |
| Rifampicine | Raises teriflunomide levels (counter-intuitive; not via CYP3A4 induction) | Use with caution; consider lower leflunomide dose. |
| Cholestyramine, activated charcoal | Dramatically lowers teriflunomide levels — the basis of the washout protocol | Avoid co-administration except when washout is intended. |
| Live vaccines | Risk of disseminated vaccine-strain infection | Contraindicated. Use inactivated alternatives. |
| Other DMARDs and biologics (TNF inhibitors, JAK inhibitors, abatacept, rituximab) | Additive immunosuppression and infection risk | Specialist combination therapy; consider PCP and antiviral prophylaxis. |
| OAT3 substrates (cefaclor, ciprofloxacin, indomethacin, ketoprofen) | Teriflunomide may raise their plasma levels | Monitor for adverse effects of the partner drug. |
| Repaglinide and other CYP2C8 substrates | Teriflunomide raises levels of CYP2C8 substrates | Monitor for adverse effects; reduce repaglinide dose. |
Bewaaradvies
- Bewaren bij kamertemperatuur, below 25°C, protected from light and moisture.
- Bewaar tabletten in de originele blisterverpakking tot gebruik.
- Do not store in the bathroom.
- Buiten bereik van kinderen houden.
- Do not use after the expiry date on the pack.
- Return unused tablets to a pharmacy for disposal.
Gerelateerde alternatieven op MedsBase
Other medications used in anti-inflammatory and autoimmune care stocked alongside this product:
- Barinat (baricitinib 2 / 4 mg) — JAK1/2 inhibitor for RA
- Tofe (tofacitinib 5 mg) — JAK1/3 inhibitor for RA, UC, PsA
- Azoran (azathioprine 50 mg) — classic immunosuppressant DMARD
- Conimune ME (cyclosporine) — calcineurin inhibitor
- Wysolone (prednisolone 5 / 10 / 20 mg) — oral corticosteroid
- Medrol (methylprednisolone 4 / 8 / 16 mg) — oral corticosteroid
- Predniheal (prednisolone) — oral corticosteroid
- Hisone (hydrocortisone) — physiologic replacement steroid
- Budez CR (budesonide) — gut-targeted corticosteroid for Crohn's
- Kenacort (triamcinolone) — systemic corticosteroid
Explore the full Ontstekingsremmende & Auto-immuunzorg category.
Veelgestelde vragen
How long does Lefuheal take to work?
First signs of joint-pain improvement at 4–6 weken; meaningful reduction in swelling and morning stiffness usually at 6–12 weeks; full effect on disease activity at 12–24 weeks. The slow time-course is one of the harder aspects of leflunomide therapy — many patients want to give up at week 6 because they do not yet feel benefit. The expectation must be set explicitly at the start.
Why must both my partner and I use contraception on Lefuheal?
Teriflunomide (the active metabolite) is strongly teratogenic in animal studies and probably in humans — it is rated Pregnancy Category X. Female patients must use effective contraception throughout therapy and for at least 2 years after stopping (or until cholestyramine washout has confirmed plasma level < 0.02 mg/L on two separate samples 14 days apart). Male patients on leflunomide whose female partner could become pregnant should use barrier contraception — teriflunomide is detectable in semen and theoretical risk to a developing fetus is real. If pregnancy is desired, plan well in advance and arrange the cholestyramine washout BEFORE attempting to conceive.
What is the cholestyramine washout protocol?
Teriflunomide undergoes enterohepatic recirculation, so it persists in plasma for up to 2 years after stopping leflunomide. Cholestyramine 8 g three times daily for 11 days binds teriflunomide in the gut, breaking the recirculation loop and rapidly clearing the drug. After 11 days, plasma teriflunomide is measured; once it is < 0.02 mg/L on two separate samples 14 days apart, washout is complete. Used for pregnancy planning, severe adverse reaction, severe infection, or rapid switch to a different therapy.
Will I get diarrhoea on Lefuheal?
About 1 in 5 patients get clinically significant diarrhoea, usually in the first 2–3 months. Strategies that help: skip the loading dose, start at 10 mg/day (uptitrate to 20 if tolerated), take with food, time the dose to your routine. If diarrhoea persists despite these, a brief course of cholestyramine can rapidly clear active drug; the rheumatologist may then restart at a lower dose or switch to a different DMARD. Most patients who tolerate weeks 1–3 do well long-term.
Will my hair fall out on Lefuheal?
Mild hair thinning or shedding affects about 10–20% of users, usually starting at 2–3 months and partially settling. Frank alopecia is uncommon. Hair loss is fully reversible after stopping the drug. Mitigations: switching to 10 mg/day, biotin and zinc supplementation, gentle hair handling. If severe and distressing, discussion with the rheumatologist about an alternative DMARD is reasonable.
Can I drink alcohol on Lefuheal?
Alcohol meaningfully increases the risk of leflunomide hepatotoxicity. Most rheumatologists advise no more than 1–2 alcoholic units per week on leflunomide monotherapy, and none at all on leflunomide + methotrexate combination. If LFTs are persistently mildly elevated, alcohol should be discontinued entirely.
What blood tests do I need on Lefuheal?
FBC, LFTs (ALT, AST, ALP, bilirubin) and BP at baseline; then monthly for 6 months; then every 3 months indefinitely. More frequent during periods of intercurrent illness, alcohol consumption, or dose change. Any rise in ALT or AST > 2–3× the upper limit of normal triggers a prescriber review and usually a dose reduction or interruption. WCC drop below 3.0 × 10&sup9;/L or platelets below 100 × 10&sup9;/L are also stopping triggers.
Can I have live vaccines on Lefuheal?
No. Live vaccines — MMR, varicella, yellow fever, BCG, live nasal flu, live Zostavax shingles vaccine — are contraindicated during therapy and for 2 years after stopping (or until cholestyramine washout has confirmed adequate clearance). Plan all live vaccines BEFORE starting where possible. Inactivated vaccines — annual flu jab, pneumococcal, COVID-19, recombinant Shingrix, HPV — are fine and recommended.
Can Lefuheal be used in combination with biologics or JAK inhibitors?
Yes — combination of leflunomide with TNF inhibitors (etanercept, adalimumab), abatacept, rituximab, or JAK inhibitors (tofacitinib, baricitinib) is a standard rheumatology approach for resistant disease. The trade-off is a higher risk of serious infection. Specialist supervision is essential; PCP prophylaxis (co-trimoxazole) and antiviral prophylaxis (aciclovir, valaciclovir) are sometimes added.
Waarom bestellen bij MedsBase
Lefuheal is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our Reshipment Assurance Policy. Uw betalingsbeschrijving bij betaling per kaart toont de gereguleerde betalingsverwerker (een gereguleerde kaartbetalingverwerker), nooit “MedsBase” of een medicijnnaam.
Other Anti-Inflammatory & Autoimmune Medications
If Lefuheal does not suit your situation, the following options are available in this category:
- Azoran (Azathioprine 50 mg, RPG) — purine antimetabolite
- Conimune ME (Cyclosporine 25/50/100 mg) — calcineurin inhibitor
- Barinat (Baricitinib 2/4 mg, Cipla) — JAK1/JAK2 inhibitor
- Tofe (Tofacitinib 5 mg, Intas) — pan-JAK inhibitor
- Wysolone (Prednisolone 5/10/20 mg) — bridging corticosteroid
More options in Anti Inflammatory & Autoimmune Care
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 10 mg, 20 mg |
|---|---|
| Hoeveelheid | 30 Tabletten, 60 Tabletten, 90 Tabletten, 180 Tabletten |
Lefuheal
Vragen & antwoorden
Lefuheal
Gerelateerde producten
Beoordelingen
Er zijn nog geen beoordelingen